Scemblix

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

asciminib hydrochloride

Available from:

Novartis Europharm Limited

ATC code:

L01EA06

INN (International Name):

asciminib

Therapeutic group:

Aġenti antineoplastiċi

Therapeutic area:

Lewkimja, mjeloġenika, kronika, BCR-ABL pożittiva

Therapeutic indications:

Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Product summary:

Revision: 3

Authorization status:

Awtorizzat

Authorization date:

2022-08-25

Patient Information leaflet

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan se jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Scemblix 20 mg pilloli miksija b’rita
Scemblix 40 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Scemblix 20 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 21.62 mg asciminib hydrochloride,
ekwivalenti għal 20 mg asciminib.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 43 mg monoidrat tal-lattosju.
Scemblix 40 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 43.24 mg asciminib hydrochloride,
ekwivalenti għal 40 mg asciminib.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 86 mg monoidrat tal-lattosju.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Scemblix 20 mg pilloli miksija b’rita
Pilloli miksija b’rita ta’ lewn isfar ċar, tondi, bikonvessi
bit-truf imċanfrin b’dijametru ta’ madwar
6 mm, ittimbrati bil-logo tal-kumpanija fuq naħa minnhom u
b’“20” fuq in-naħa l-oħra.
Scemblix 40 mg pilloli miksija b’rita
Pilloli miksija b’rita ta’ lewn abjad fil-vjola, tondi, bikonvessi
bit-truf imċanfrin b’dijametru ta’
madwar 8 mm, ittimbrati bil-logo tal-kumpanija fuq naħa minnhom u
b’“40” fuq in-naħa l-oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Scemblix huwa indikat għat-trattament ta’ pazjenti adulti
b’lewċemija tal-majelojde bil-kromożoma
Philadelphia pożittiva f’fażi kronika (Ph+ CML-CP) li ngħataw
trattament qabel b’żewġ inibituri tat-
tirosina kinasi jew aktar (ara sezzjoni 5.1).
3
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
It-trattament g
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
Dan il-prodott mediċinali huwa suġġett għal monitoraġġ
addizzjonali. Dan se jippermetti
identifikazzjoni ta’ malajr ta’ informazzjoni ġdida dwar
is-sigurtà. Il-professjonisti tal-kura tas-saħħa
huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata. Ara
sezzjoni 4.8 dwar kif
għandhom jiġu rappurtati reazzjonijiet avversi.
1.
ISEM IL-PRODOTT MEDIĊINALI
Scemblix 20 mg pilloli miksija b’rita
Scemblix 40 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Scemblix 20 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 21.62 mg asciminib hydrochloride,
ekwivalenti għal 20 mg asciminib.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 43 mg monoidrat tal-lattosju.
Scemblix 40 mg pilloli miksija b’rita
Kull pillola miksija b’rita fiha 43.24 mg asciminib hydrochloride,
ekwivalenti għal 40 mg asciminib.
_Eċċipjent b’effett magħruf_
Kull pillola miksija b’rita fiha 86 mg monoidrat tal-lattosju.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita (pillola).
Scemblix 20 mg pilloli miksija b’rita
Pilloli miksija b’rita ta’ lewn isfar ċar, tondi, bikonvessi
bit-truf imċanfrin b’dijametru ta’ madwar
6 mm, ittimbrati bil-logo tal-kumpanija fuq naħa minnhom u
b’“20” fuq in-naħa l-oħra.
Scemblix 40 mg pilloli miksija b’rita
Pilloli miksija b’rita ta’ lewn abjad fil-vjola, tondi, bikonvessi
bit-truf imċanfrin b’dijametru ta’
madwar 8 mm, ittimbrati bil-logo tal-kumpanija fuq naħa minnhom u
b’“40” fuq in-naħa l-oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Scemblix huwa indikat għat-trattament ta’ pazjenti adulti
b’lewċemija tal-majelojde bil-kromożoma
Philadelphia pożittiva f’fażi kronika (Ph+ CML-CP) li ngħataw
trattament qabel b’żewġ inibituri tat-
tirosina kinasi jew aktar (ara sezzjoni 5.1).
3
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
It-trattament g
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 12-01-2024
Public Assessment Report Public Assessment Report Bulgarian 07-09-2022
Patient Information leaflet Patient Information leaflet Spanish 12-01-2024
Public Assessment Report Public Assessment Report Spanish 07-09-2022
Patient Information leaflet Patient Information leaflet Czech 12-01-2024
Public Assessment Report Public Assessment Report Czech 07-09-2022
Patient Information leaflet Patient Information leaflet Danish 12-01-2024
Public Assessment Report Public Assessment Report Danish 07-09-2022
Patient Information leaflet Patient Information leaflet German 12-01-2024
Public Assessment Report Public Assessment Report German 07-09-2022
Patient Information leaflet Patient Information leaflet Estonian 12-01-2024
Public Assessment Report Public Assessment Report Estonian 07-09-2022
Patient Information leaflet Patient Information leaflet Greek 12-01-2024
Public Assessment Report Public Assessment Report Greek 07-09-2022
Patient Information leaflet Patient Information leaflet English 12-01-2024
Public Assessment Report Public Assessment Report English 07-09-2022
Patient Information leaflet Patient Information leaflet French 12-01-2024
Public Assessment Report Public Assessment Report French 07-09-2022
Patient Information leaflet Patient Information leaflet Italian 12-01-2024
Public Assessment Report Public Assessment Report Italian 07-09-2022
Patient Information leaflet Patient Information leaflet Latvian 12-01-2024
Public Assessment Report Public Assessment Report Latvian 07-09-2022
Patient Information leaflet Patient Information leaflet Lithuanian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 12-01-2024
Public Assessment Report Public Assessment Report Lithuanian 07-09-2022
Patient Information leaflet Patient Information leaflet Hungarian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 12-01-2024
Public Assessment Report Public Assessment Report Hungarian 07-09-2022
Patient Information leaflet Patient Information leaflet Dutch 12-01-2024
Public Assessment Report Public Assessment Report Dutch 07-09-2022
Patient Information leaflet Patient Information leaflet Polish 12-01-2024
Public Assessment Report Public Assessment Report Polish 07-09-2022
Patient Information leaflet Patient Information leaflet Portuguese 12-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 12-01-2024
Public Assessment Report Public Assessment Report Portuguese 07-09-2022
Patient Information leaflet Patient Information leaflet Romanian 12-01-2024
Public Assessment Report Public Assessment Report Romanian 07-09-2022
Patient Information leaflet Patient Information leaflet Slovak 12-01-2024
Public Assessment Report Public Assessment Report Slovak 07-09-2022
Patient Information leaflet Patient Information leaflet Slovenian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 12-01-2024
Public Assessment Report Public Assessment Report Slovenian 07-09-2022
Patient Information leaflet Patient Information leaflet Finnish 12-01-2024
Public Assessment Report Public Assessment Report Finnish 07-09-2022
Patient Information leaflet Patient Information leaflet Swedish 12-01-2024
Public Assessment Report Public Assessment Report Swedish 07-09-2022
Patient Information leaflet Patient Information leaflet Norwegian 12-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 12-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 12-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 12-01-2024
Patient Information leaflet Patient Information leaflet Croatian 12-01-2024
Public Assessment Report Public Assessment Report Croatian 07-09-2022

Search alerts related to this product

View documents history